This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Discussant Judy Garber, MD, MPH

JAMA. 1999;282:1953-1960.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

DR DALEY: Mrs T is a 40-year-old married mother of 3 children with a strong family history of breast cancer who is considering genetic testing and tamoxifen therapy. She lives on Cape Cod, Mass, and works at home caring for her 3 children, ages 7, 5, and 2. Her health insurance is provided through a managed care plan.

Mrs T is in good health. She is of Dutch and English ancestry. Her maternal grandmother was diagnosed with breast cancer in her seventh decade and was treated with surgery. She died of causes unrelated to breast cancer. Mrs T's mother developed breast cancer and died of complications related to breast cancer metastatic to bone. Her sister developed breast cancer at age 26 and died at age 38 of complications related to metastatic breast cancer to lymphatics and lung. Mrs T has had yearly mammography since age . . . [Full Text of this Article]

MRS T: HER UNDERSTANDING AND PERCEPTIONS

AT THE CROSSROADS: QUESTIONS TO DR GARBER

DR GARBER:

Estimating Breast Cancer Risk

Why Not Test Every Woman for BRCA1 and BRCA2?

Genetic Testing Scenarios

Factors Influencing the Decision to Undergo Genetic Testing

Medical Management of Inherited Breast Cancer Risk

CONCLUSION

QUESTIONS AND DISCUSSION

Author Affiliation: Dr Garber is Director, Cancer Risk and Prevention, Department of Adult Oncology, Dana-Farber Cancer Institute and Assistant Professor of Medicine, Harvard Medical School, Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

November 24, 1999
JAMA. 1999;282(20):1979-1980.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

From a Genetic Predisposition to an Interactive Predisposition: Rethinking the Ethical Implications of Screening for Gene-Environment Interactions
Tabery
J Med Philos 2009;0:jhn039v1-jhn039.
ABSTRACT | FULL TEXT  

Firing up the nature/nurture controversy: bioethics and genetic determinism
de Melo-Martin
J. Med. Ethics 2005;31:526-530.
ABSTRACT | FULL TEXT  

Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model
Col et al.
Med Decis Making 2002;22:386-393.
ABSTRACT  

Women's Interest in Chemoprevention for Breast Cancer
Bastian et al.
Arch Intern Med 2001;161:1639-1644.
ABSTRACT | FULL TEXT  

Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model
Bosompra et al.
Health Educ Res 2001;16:157-172.
ABSTRACT | FULL TEXT  

A 40-Year-Old Woman With a Strong Family History of Breast Cancer, 1 Year Later
Hartman and Parker
JAMA 2000;283:3243-3243.
FULL TEXT